484 related articles for article (PubMed ID: 11857288)
1. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
2. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
4. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
5. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
Aydin S; Dührsen U; Nückel H
Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Tsimberidou AM; O'Brien SM; Cortes JE; Faderl S; Andreeff M; Kantarjian HM; Keating MJ; Giles FJ
Leuk Lymphoma; 2002 Apr; 43(4):767-72. PubMed ID: 12153163
[TBL] [Abstract][Full Text] [Related]
7. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
Chau I; Webb A; Cunningham D; Hill M; Rao S; Ageli S; Norman A; Gill K; Howard A; Catovsky D
Br J Haematol; 2001 Dec; 115(4):786-92. PubMed ID: 11843810
[TBL] [Abstract][Full Text] [Related]
8. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.
Machover D; Delmas-Marsalet B; Misra SC; Gumus Y; Goldschmidt E; Schilf A; Frénoy N; Emile JF; Debuire B; Guettier C; Farrokhi P; Boulefdaoui B; Norol F; Parquet N; Ulusakarya A; Jasmin C
Ann Oncol; 2001 Oct; 12(10):1439-43. PubMed ID: 11762817
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
11. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
12. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Ho AD; del Valle F; Rückle H; Schwammborn J; Schlimok G; Hiddemann W; Meusers P; Thiel E; Dörken B; Hunstein W
Cancer; 1989 Oct; 64(7):1388-92. PubMed ID: 2776103
[TBL] [Abstract][Full Text] [Related]
15. FLUDAP: salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Child JA; Johnson SA; Rule S; Smith GM; Morgan GJ; Johnson PW; Prentice AG; Tollerfield SM; Wareham E
Leuk Lymphoma; 2000 Apr; 37(3-4):309-17. PubMed ID: 10752982
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
[TBL] [Abstract][Full Text] [Related]
17. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
[TBL] [Abstract][Full Text] [Related]
19. Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas.
Lossos IS; Paltiel O; Polliack A
Leuk Lymphoma; 1999 Mar; 33(1-2):155-60. PubMed ID: 10194133
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.
Nückel H; Dürig J; Dührsen U
Ann Hematol; 2003 Aug; 82(8):481-486. PubMed ID: 12910375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]